Every material Form 8-K Lumexa Imaging Holdings, Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lumexa Imaging reported second quarter 2026 revenue of $264.2 million, up 5.1% from a year earlier, and net income of $2.7 million, compared with a net loss of $7.2 million in the same quarter of 2025. The company reiterated its full-year 2026 revenue guidance and narrowed its Adjusted EBITDA range to $235 million to $241 million, leaving the midpoint at $238 million.
Q2 2026 revenue of $264.2 million vs. $251.4 million; system-wide revenue growth of 6.0%
Net income of $2.7 million, or $0.03 per diluted share, vs. a net loss of $7.2 million a year earlier
Adjusted EBITDA of $56.4 million vs. $56.3 million; Adjusted EBITDA margin fell to 21.4% from 22.4%
Full-year 2026 guidance: revenue $1.045 billion to $1.097 billion (reiterated); Adjusted EPS $0.71 to $0.77 (reiterated)
Subsidiaries of Lumexa Imaging Holdings, Inc. amended their existing credit agreement on June 30, 2026, providing a secured term loan of approximately $823 million and a secured $250 million revolving credit line. The filing describes new restrictive covenants, a leverage test that applies if revolver usage exceeds 40%, and guarantees and collateral pledged by most subsidiaries, which shareholders should weigh as added debt and lender constraints.
Replacement term loan of approximately $823 million matures in December 2032, priced at SOFR plus 2.50% or Prime plus 1.50%.
Revolving credit facility of $250 million matures in December 2030, with pricing at SOFR plus 2.50% or Prime plus 1.50%, subject to reduction on certain leverage ratios.
If revolver exposure exceeds 40% of the facility at quarter-end, the consolidated net leverage ratio must not exceed 7.50 to 1.
Barclays Bank PLC is administrative agent; the loans are guaranteed and secured by substantially all wholly-owned subsidiaries' assets, subject to exceptions.
Lumexa Imaging reported first quarter 2026 revenue of $252.5 million, up 3.1% from $245.0 million a year earlier, and swung to net income of $1.7 million from a net loss of $7.7 million. The company reiterated its full year 2026 guidance and said it is adding four centers, including two tuck-in acquisitions and two de novo centers.
Consolidated revenue of $252.5 million, up 3.1% from $245.0 million; same-center advanced volume growth of 5.6%
Net income of $1.7 million (GAAP EPS $0.02) versus a net loss of $7.7 million (EPS of $(0.11)) a year earlier
Adjusted EBITDA of $51.2 million versus $51.0 million, a 20.3% margin; Adjusted EPS of $0.18 versus $0.04
Full year 2026 guidance reiterated: revenue of $1.045 to $1.097 billion and Adjusted EBITDA of $234 to $242 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lumexa Imaging Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →